Please login to the form below

Not currently logged in
Email:
Password:

ADC

This page shows the latest ADC news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Global Blood confident of sickle cell success, Breathalyser wins engineering award, Swiss biotech raises funds

Daily brief: Global Blood confident of sickle cell success, Breathalyser wins engineering award, Swiss biotech raises funds

The Swiss company's lead programme, NBE-002 targeting ROR-1, is being developed primarily for the treatment of solid tumours, and will now move into clinical development, with further ADC

Latest news

More from news
Approximately 2 fully matching, plus 59 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... As an ADC IMMU-132 contains SN-38,

  • Deal Watch January 2017 Deal Watch January 2017

    465. Abzena. Not disclosed. Licence. ThioBridge ADC linker technology. 300. Domain Therapeutics.

  • Deal Watch February 2016 Deal Watch February 2016

    Mersana could receive an additional $750m in milestones if the XMT-1522 and ADC programmes are successful, plus sales royalties. ... acquisition - company. 895. Mersana Therapeutics/ Takeda. XMT-1522, Fleximer-based ADC therapy targeting HER2-expressing

  • Deal Watch January 2016 Deal Watch January 2016

    Abzena/(Partner nd). Licence . Novel site specific ThioBridge antibody drug conjugate (ADC) linker technology.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Late to join the immuno-oncology race, ADC 1013 is a CD40 targeting antibody in phase I clinical studies; J&J assumes development responsibilities when the phase I studies are completed. ... Licence. 727. Alligator Bioscience. J&J. ADC 1013 in solid

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    His experience in advancing scientific discoveries from the lab to commercialisation will be invaluable in helping us fully exploit our unique ADC platform, both in the development of our proprietary product

  • ADC Therapeutics expands team ADC Therapeutics expands team

    ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Michael Forer, CEO of ADC Therapeutics, said: “ The quality of individuals and depth of experience that we

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    conjugates (ADCs) for cancer.

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics